PRESS RELEASE

Intravacc and ViciniVax sign license agreement to advance the development of a novel vaccine against cervical cancer

Bilthoven / Groningen, the Netherlands, 13th March 2013

Intravacc, the Institute for Translational Vaccinology based in Bilthoven, The Netherlands and ViciniVax, a Dutch biotech company in Groningen, announced today that they signed a license agreement on the use of Intravacc’s Vero production cell line for vaccine development.

Under the terms of the agreement, ViciniVax will have a non-exclusive license to use the Vero cell line platform technology of Intravacc for development of a therapeutic vaccine against cervical cancer ‘Vvax001’. In addition, ViciniVax will receive master and working cell banks. The development of Vvax001 is foreseen to enter clinical stage in Q1 of 2014.

Cervical cancer is one of the main types of cancer in women and causes worldwide about 275,000 deaths per year. A vaccine to protect against the disease is available but is only effective in 70% of the cases. In addition, the current preventive vaccine does not work for people already affected by the disease. Therefore, the development of a therapeutic vaccine against cervical cancer can be a great step forward in the fight against cervical cancer.

About Intravacc
Intravacc, incorporating the former vaccine development division of the National Institute for Public Health and the Environment (RIVM), was demerged from RIVM on January 1, 2013. Intravacc is a non profit, government-based, vaccine institute with extensive knowledge and experience in the field of vaccine development. Their Vero cell line platform technology is successfully used for the development, registration and production of vaccines. The longstanding usage and well-known safety profile of vaccines that are produced on Vero cells make the Vero cell production platform the reliable standard for cell-based vaccine production.

About ViciniVax
ViciniVax is a Dutch biotechnology company, spin-off from the University Medical Center Groningen, The Netherlands. ViciniVax’ first product candidate is Vvax001, a therapeutic cancer vaccine against (pre)malignant cervical lesions, currently in pre-clinical development. Vvax001 is a recombinant viral vector, specifically modified to elicit a strong immunological anti-tumor response after vaccination. A first financing round was closed in 2011 to be able to pursue the clinical development of Vvax001. Process development and GMP manufacturing is outsourced to experienced CMOs.
Note for the editors

Contact
Ernst Soethout, PhD                        Alfred N. Nijkerk, CEO
Phone: +31 6 25043475                      Phone: +31 6 5512 8387
Email: ernst.soethout@intravacc.nl        Email: nijkerk@vicinivax.com

Intravacc

Antonie van Leeuwenhoeklaan 9              ViciniVax BV
3721 MA Bithoven                            Meditech Center
The Netherlands                           L.J. Zielstraweg 1
www.intravacc.nl                           9713 GX Groningen
                                           the Netherlands
                                           www.vicinivax.com